Johnson & Johnson reported a significantly lower overall efficacy figure in interim data from the first Phase III trial of its single-dose vaccine against SARS-CoV-2 than those of competitors, causing widespread disappointment and concerns about its efficacy, particularly in the context of worries about a South African variant of the virus that has arrived in the US. But the company has suggested there is more than meets the eye.
The New Brunswick, NJ-based drug maker reported on 29 January data from the Phase III ENSEMBLE trial of JNJ-78436735, also...






